{"title":"Single-center experience in the diagnosis and treatment of hepatic angiosarcoma.","authors":"Jian Yu, Junjun Jia, Jiabin Liu, Zhou Shao, Feng Gao, Songfeng Yu, Min Zhang","doi":"10.21037/cco-24-116","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Primary hepatic angiosarcoma (PHA) is a rare but aggressive liver tumor, accounting for ~5% of all hemangiosarcomas and <2% of all primary hepatic malignancies. Oncological treatment data on PHA remain limited at present. The objective of this single-center study was to summarize the diagnosis and treatment of PHA, thereby contributing additional clinical data to improve understanding of the disease.</p><p><strong>Methods: </strong>Eight patients were diagnosed with PHA in The First Affiliated Hospital, Zhejiang University School of Medicine from 2016 to 2022. Five patients were male and three were female with a mean age of 62.4 years (range, 38-74 years). We summarized the clinical characteristics, pathological parameters, and treatment based on the electronic medical record system.</p><p><strong>Results: </strong>Among the 8 patients with PHA, four patients presented with abdominal distension and pain, and two with weakness. The diagnosis was confirmed by pathological findings. Four patients underwent surgery and four received conventional treatment. Seven patients died within 14 months due to tumor progression and the median survival time was 2 months.</p><p><strong>Conclusions: </strong>PHA is a rare malignant liver tumor, and there are no specific symptoms or imaging methods for preoperative diagnosis. The diagnosis can only be confirmed by pathology and the prognosis is poor. Early diagnosis is crucial and further studies are needed to develop standardized diagnostic and treatment guidelines.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"14 3","pages":"28"},"PeriodicalIF":2.1000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/cco-24-116","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Primary hepatic angiosarcoma (PHA) is a rare but aggressive liver tumor, accounting for ~5% of all hemangiosarcomas and <2% of all primary hepatic malignancies. Oncological treatment data on PHA remain limited at present. The objective of this single-center study was to summarize the diagnosis and treatment of PHA, thereby contributing additional clinical data to improve understanding of the disease.
Methods: Eight patients were diagnosed with PHA in The First Affiliated Hospital, Zhejiang University School of Medicine from 2016 to 2022. Five patients were male and three were female with a mean age of 62.4 years (range, 38-74 years). We summarized the clinical characteristics, pathological parameters, and treatment based on the electronic medical record system.
Results: Among the 8 patients with PHA, four patients presented with abdominal distension and pain, and two with weakness. The diagnosis was confirmed by pathological findings. Four patients underwent surgery and four received conventional treatment. Seven patients died within 14 months due to tumor progression and the median survival time was 2 months.
Conclusions: PHA is a rare malignant liver tumor, and there are no specific symptoms or imaging methods for preoperative diagnosis. The diagnosis can only be confirmed by pathology and the prognosis is poor. Early diagnosis is crucial and further studies are needed to develop standardized diagnostic and treatment guidelines.
期刊介绍:
The Chinese Clinical Oncology (Print ISSN 2304-3865; Online ISSN 2304-3873; Chin Clin Oncol; CCO) publishes articles that describe new findings in the field of oncology, and provides current and practical information on diagnosis, prevention and clinical investigations of cancer. Specific areas of interest include, but are not limited to: multimodality therapy, biomarkers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to cancer. The aim of the Journal is to provide a forum for the dissemination of original research articles as well as review articles in all areas related to cancer. It is an international, peer-reviewed journal with a focus on cutting-edge findings in this rapidly changing field. To that end, Chin Clin Oncol is dedicated to translating the latest research developments into best multimodality practice. The journal features a distinguished editorial board, which brings together a team of highly experienced specialists in cancer treatment and research. The diverse experience of the board members allows our editorial panel to lend their expertise to a broad spectrum of cancer subjects.